Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance

Journal of Immunology

Volumn 168, Issue 2, 2002, Pages 933-941

  Von Herrath, M G ^a   Coon, B ^a   Wolfe, T ^a   Chatenoud, L ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY CD3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNE DIABETES; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; IMMUNOCOMPETENCE; IMMUNOPATHOGENESIS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0037080225     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.168.2.933     Document Type: Article

References (51)

1. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts
2. Treatment of acute renal allograft rejection with OKT3 monoclonal antibody
3. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants
4. One-month prophylactic use of Okt3 in cadaver kidney transplant recipients
5. The long-term effects of prophylactic OKT3 monoclonal antibody in cadaver kidney transplantation: A single-center, prospective, randomized study
6. Prevention of autoimmune diabetes with non-activating anti-CD3 monoclonal antibody
7. Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody
8. 2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation
9. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice
10. Induction of specific tolerance to allografts in rats by therapy with non-mitogenic, non-depleting anti-CD3 monoclonal antibody: Association with TH2 cytokines not anergy
11. Critical roles for IL-4, IL-5, and eosinophils in chronic skin allograft rejection
12. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice
13. The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties
14. A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo
15. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3γl(Ala-Ala) in the treatment of acute renal allograft rejection
16. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection
17. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: Further evidence for transient in vivo T cell activation
18. Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-γ, interleukin 3 and interleukin 6 release after triggering of the CD3/T cell receptor activation pathway
19. Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: Role of tumor necrosis factor
20. In vivo induction of interleukin 10 by anti-CD3 monoclonal antibody or bacterial lipopolysaccharide: Differential modulation by cyclosporin A
21. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome: Dosage and kinetics prerequisites
22. Release of tumor necrosis factor, interleukin-2, and γ-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients
23. Biologic immunosuppressive agents
24. Tolerance to islet autoantigens in type 1 diabetes
25. Restoration of self-tolerance is a feasible approach to control ongoing β-cell specific autoreactivity: Its relevance for treatment in established diabetes and islet transplantation
26. Report from the 1st International Workshop, and the follow-up mini-workshop, on T cell responses in the NOD mouse: NOD mice display consistent responses to some β-cell autoantigens, but the magnitude varies between colonies
27. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: Role of anti-self (virus) immune response
28. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model
29. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice
30. Virus-induced autoimmune diabetes: Most β-cells die through inflammatory cytokines and not perforin from autoreactive (anti-viral) cytotoxic T-lymphocytes
31. b major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes
32. + T cell subsets during virus infection: Protective capacity depends on effector cytokine secretion and on migratory capability
33. Oral insulin treatment suppresses virus-induced antigen-specific destruction of β cells and prevents autoimmune diabetes in transgenic mice
34. Identification of a monoclonal antibody specific for a murine T3 polypeptide
35. Insulin in oral immune "tolerance": A one-amino acid change in the B chain makes the difference
36. + T cells protect from autoimmune diabetes via bystander suppression using the IL-4/Stat6 pathway
37. Evidence for an underlying CD4 helper and CD8 T-cell defect in B-cell-deficient mice: Failure to clear persistent virus infection after adoptive immunotherapy with virus-specific memory cells from μMT/μMT mice
38. A dual role for TNF-α on type 1 diabetes: Islet specific expression abrogates the ongoing autoimmune process when induced late but not early during pathogenesis
39. CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge
40. + naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance
41. The activity of immunoregulatory T cells mediating active tolerance is potentiated in nonobese diabetic mice by an IL-4-based retroviral gene therapy
42. Effects of in vivo administration of anti-T3 monoclonal antibody on T cell function in mice. I. Immunosuppression of transplantation responses
43. Thymic tolerance to only one viral protein reduces lymphocytic choriomeningitis virus-induced immunopathology and increases survival in perforin-deficient mice
44. In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes
45. Antigenic modulation: A major mechanism of antibody action
46. Focal expression of interleukin-2 does not break unresponsiveness to "self" (viral) antigen expressed in β cells but enhances development of autoimmune disease (diabetes) after initiation of an anti-self immune response
47. Reversal of β-cell suppression in vitro in pancreatic islets isolated from nonobese diabetic mice during the phase preceding insulin-dependent diabetes mellitus
48. Increased β-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse
49. Coexpression of B7-1 and viral ("self") transgenes in pancreatic β cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes
50. + thymocytes expressing L-selectin mediate "active tolerance" in the nonobese diabetic mouse
51. (+) T cells that prevent diabetes onset in nonobese diabetic mice